Este sitio web utiliza tecnologías de seguimiento, como cookies, para brindar una mejor experiencia al usuario. Si continúa utilizando este sitio, entonces reconoce nuestro uso de tecnologías de seguimiento. Para obtener información adicional, consulte nuestra Política de Privacidad.
REGÍSTRESE
One of the key risk factors for colorectal cancer is inflammatory bowel disease, like Crohn’s disease and ulcerative colitis. These diseases are driven by chronic inflammatory responses to the gut microbiome and are associated with dysbiotic changes in the microbiome composition. Dr. Duncan-Lowey’s study will focus on understanding the molecular interactions between gut microbes and human hosts and defining how these interactions are different between healthy people and patients with inflammatory bowel disease. Understanding these differences can help define what changes in the microbiome may cause inflammation, and how changes in the intestinal layers may change which microbes are able to reside in the gut. These insights can lead to a new understanding of to how to treat inflammatory bowel disease and mitigate inflammation to decrease the risk of colorectal cancer.
Yale University | All Cancers | 2022 | Noah Palm, Ph.D.
Comuníquese con nosotros
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Directorio de Personal
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).